Join the Lumryz group to help and get support from people like you.
Lumryz News
Sodium Oxybate Beneficial for Alcohol-Responsive Laryngeal Dystonia
WEDNESDAY, Nov. 27, 2024 – Sodium oxybate improves symptoms of alcohol-responsive (EtOH-positive) isolated laryngeal dystonia (LD), according to a study published online Nov. 20 in the Annals of...
Monthly News Roundup - October 2024
FDA Approves AbbVie’s Vyalev to Treat Advanced Parkinson Disease In October, the US Food and Drug Administration (FDA) approved Vyalev (foscarbidopa and foslevodopa) for the treatment of motor f...
Avadel Pharmaceuticals Announces FDA Approval of Lumryz (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
DUBLIN, Oct. 17, 2024 (GLOBE NEWSWIRE) – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S....
FDA Approves Lumryz (sodium oxybate) for Cataplexy or Excessive Daytime Sleepiness in Adults with Narcolepsy
DUBLIN, May 01, 2023 (GLOBE NEWSWIRE) – Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the U.S....